-
公开(公告)号：US11000601B2
公开(公告)日：2021-05-11
申请号：US15820309
申请日：2017-11-21
Applicant: OBI Pharma, Inc.
Inventor： Michael Nientse Chang , Jiann-Shiun Lai , Wan-Fen Li , I-Ju Chen , Yi-Chien Tsai , Kai-Chuan Chen
IPC: A61K47/68 , C08B37/00 , A61K45/06 , A61K39/395 , G01N33/574 , A61K51/10 , A61K49/16 , A61K49/00 , A61P35/04 , C07K16/18 , C07K16/30 , A61P35/00 , C07K16/44 , A61K39/00
Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
-
公开(公告)号：US20210113711A1
公开(公告)日：2021-04-22
申请号：US17133388
申请日：2020-12-23
Applicant: OBI Pharma, Inc.
Inventor： Michael Nientse Chang , Jiann-Shiun Lai , Wan-Fen Li , I-Ju CHEN , Yi-Chien Tsai , Kai-Chuan Chen
IPC: A61K47/68 , C08B37/00 , A61K45/06 , A61K39/395 , G01N33/574 , A61K51/10 , A61K49/16 , A61K49/00 , A61P35/04 , C07K16/18 , C07K16/30 , A61P35/00 , C07K16/44
Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
-
公开(公告)号：US20200048334A1
公开(公告)日：2020-02-13
申请号：US16547009
申请日：2019-08-21
Applicant: OBI PHARMA, INC.
Inventor： Cheng-Der Tony YU , Jiann-Shiun LAI , I-Ju CHEN
Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
-
公开(公告)号：US10517936B2
公开(公告)日：2019-12-31
申请号：US14758319
申请日：2014-01-06
Applicant: OBI PHARMA, INC.
Inventor： Wei Han Lee , Nan-Hsuan Wang , Chung Hao Chang , Yih-Huang Hsieh , Cheng Der Tony Yu , Cheng-Chi Wang , Yu-Hsin Lin , Yu-Chen Lin , I-Ju Chen
Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.
-
45.发明申请公开(公告)号：US20190389963A1
公开(公告)日：2019-12-26
申请号：US16429614
申请日：2019-06-03
Applicant: OBI Pharma, Inc.
Inventor： Cheng-Der Tony YU , Jiann-Shiun LAI , Yi-Chien TSAI , Jo-Fan CHANG
Abstract: The present disclosure relates to treatment of cancer patients with anti-Globo series antigens (Globo H and SSEA-4) antibodies in combination with anti-negative immune check point antibody to rescue the inhibited T cell activity.
-
Patent Agency Ranking
公开(公告)号：US20180339061A1
公开(公告)日：2018-11-29
申请号：US15996192
申请日：2018-06-01
Applicant: OBI Pharma, Inc.
Inventor： Cheng-Der Tony YU , Jiann-Shiun LAI , I-Ju CHEN , Chiu-Chun LIN
IPC: A61K47/68 , C07K16/28 , A61P35/00 , A61K39/395 , A61K31/4025
Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
-
公开(公告)号：US20180044360A1
公开(公告)日：2018-02-15
申请号：US15557053
申请日：2016-03-09
Applicant: OBI PHARMA, INC.
Inventor： Jian-Xin Duan , Yeyu Cao , Xiaohong Cai , Hailong Jiao , Jing Yuan Ma , Mark Matteucci
IPC: C07F9/24 , G01N33/574
CPC classification number: C07F9/2466 , A61K31/396 , G01N33/57484 , G01N33/57496 , G01N2333/904 , G01N2800/52
Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
-
48.发明申请COMPOSITIONS OF A CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSES AND USES THEREOF IN CANCER TREATMENT 审中-公开用于诱导免疫应答的碳水化合物的组合物及其在癌症治疗中的用途公开(公告)号：US20150297696A1
公开(公告)日：2015-10-22
申请号：US14489182
申请日：2014-09-17
Applicant: OBI Pharma, Inc.
Inventor： Cheng-Der Tony YU , Cheng-Chi Irene Wang , Wei-Han Lee , Yu-Chen Lin , Yu-Hsin Tom Lin , I-Ju Chen
Abstract: The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.
Abstract translation: 本发明包括包括Globo H-KLH缀合物和/或治疗性抗体的治疗组合物，以及制备和使用其来治疗增殖性疾病如癌症的方法。 治疗性缀合物包括与载体连接的抗原。 特别地，治疗性缀合物包括Globo H部分和KLH部分和/或任选通过连接体连接的衍生的KLH部分亚基。 部分设想治疗组合物作为癌症疫苗，以通过免疫系统增强身体的自然保护能力，避免受损或异常细胞如癌细胞引起的危险。 有效的免疫应答是降低疾病严重性的因素，包括但不限于预防疾病，疾病发作延迟，症状严重程度降低，发病率下降和延迟死亡。
-
49.发明授权公开(公告)号：US12053514B2
公开(公告)日：2024-08-06
申请号：US14489182
申请日：2014-09-17
Applicant: OBI Pharma, Inc.
Inventor： Cheng-Der Tony Yu , Cheng-Chi Irene Wang , Wei-Han Lee , Yu-Chen Lin , Yu-Hsin Tom Lin , I-Ju Chen
CPC classification number: A61K39/001173 , A61K47/643 , A61K47/646 , G01N21/64 , A61K2039/55577 , A61K2039/6081 , A61K2039/627 , A61K2039/64
Abstract: The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.
-
公开(公告)号：US20240066125A1
公开(公告)日：2024-02-29
申请号：US18259277
申请日：2022-02-09
Applicant: OBI PHARMA, INC.
Inventor： MING-TAIN LAI , JIANN-SHIUN LAI , SHIOU-LING JIAN , JHANG-SIAN YU , WOAN-ENG CHAN
IPC: A61K39/00 , A61K35/17 , A61P35/00 , C07K16/30 , C12N5/0783
CPC classification number: A61K39/4631 , A61K35/17 , A61K39/4611 , A61P35/00 , C07K16/30 , C12N5/0636 , C07K2317/53 , C07K2317/622 , C12N2510/00
Abstract: The present disclosure relates to chimeric antigen receptors (CARs), which bind to Globo series antigens (e.g. Globo H, SSEA-3 or SSEA-4), including an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). Further, the present methods are also provided for administering CARs to a subject in an amount effective to inhibit cancer cells.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.033 seconds)
